Evidence map›Paper›PMID 41642416›Full record

ReviewCurrent oncology reports2026

THBS2 as a Key Regulator in Gastrointestinal Tumors: from Molecular Mechanisms to Clinical Applications.

Mengru Fang, Mingyang Zou, Haohua Deng, Xiaoming Li, Yajuan Zhu, Wengui Shi, Luxi Yang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengru Fang *Gansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Mingyang Zou *Department of Clinical Medicine, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China.
Haohua Deng *Department of Clinical Laboratory, The Second Hospital of Lanzhou University, Lanzhou, China.
Xiaoming LiDepartment of Clinical Medicine, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China.
Yajuan ZhuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. 2846831096@qq.com.
Wengui ShiCuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, Gansu, China. ery_danwg@lzu.edu.cn.
Luxi YangGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. yanglx2023@lzu.edu.cn.

Funding

Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital grant number CY2022-QN-A19 and CY2022-QN-A11Cuiying Scientific Training Program for Undergraduates of The SecondHospital & Clinical Medical School, Lanzhou University grant number CYXZ2024-28International science and technology cooperation project of Gansu Provincial Science and Technology Department grant number 2023YFWA0009Science and Technology Program Project of Gansu Provincial Natural Science Foundation grant number 25JRRA590The Innovation and Entrepreneurship Project for Young Talents of Lanzhou Science and Technology Bureau grant number 2023-4-18
6 · The paper itself

Abstract

purpose of reviewThrombospondin-2 (THBS2), an extracellular matrix (ECM) regulator, plays a multifaceted role in tumorigenesis. This review systematically summarizes recent advances regarding THBS2 in gastrointestinal tumors (including gastric, colorectal, pancreatic, and liver cancers) and evaluates its potential as a key player in the tumor microenvironment (TME), immune regulation, and clinical diagnostics and therapeutics. RECENT

findingsTHBS2 promotes tumor proliferation and migration by activating the MAPK/PI3K/AKT pathway via integrins. It remodels the t TME through a TGF-β1-THBS2 feedback loop involving cancer-associated fibroblasts (CAFs). Furthermore, THBS2 facilitates metastasis and immune evasion by modulating ECM structure and cytoskeletal dynamics. Emerging therapeutic strategies aim to block THBS2 interactions with CD36/CD47 to enhance anti-PD-1 immunotherapy, disrupt the TGF-β-THBS2 signaling axis, or combine with matrix metalloproteinase (MMP) inhibitors to suppress fibrosis and tumor dissemination. THBS2 acts as a critical regulator in the pathogenesis and progression of digestive tract tumors. Translating THBS2 into clinical practice requires addressing its context-dependent dual nature, tumor heterogeneity, and potential off-target resistance.

Indexed as

Gastrointestinal NeoplasmsThrombospondinsAnimalsHumansSignal TransductionThrombospondin 2Tumor MicroenvironmentThrombospondin 2ThrombospondinsColorectal cancerExtracellular matrixGastric cancerPancreatic cancerTHBS2

Identifiers

PMID41642416

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.